StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
EVFM

Evofem Biosciences, Inc.

EVFM OTC Pharmaceutical Preparations EDGAR ↗
$0.01
+0.00 +14.29%

Key statistics

from XBRL data in SEC filings
Market cap
$1.06M
Revenue (TTM)
$20.2M
Net income (TTM)
-$6.03M
EPS (TTM)
$-0.04
P/E ratio
Dividend yield
Free cash flow
-$2.00M
Cash
$1.49M
Total assets
$7.44M
Gross margin
52-week range
$0.00 – $0.02

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Regulation FD disclosure Jul 20, 2026 8-K Entered a material agreement; Took on a direct financial obligation Jul 14, 2026 8-K Results of operations (earnings release) May 18, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 8-K Entered a material agreement; Regulation FD disclosure Apr 30, 2026 8-K Entered a material agreement Apr 16, 2026 8-K Terminated a material agreement Mar 19, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Mar 11, 2026 10-K Fiscal year ended 2025-12-31 Mar 11, 2026 8-K Regulation FD disclosure Jan 12, 2026 8-K Amended charter or bylaws; Shareholder vote results Nov 26, 2025 8-K Results of operations (earnings release) Nov 13, 2025 10-Q Quarter ended 2025-09-30 Nov 13, 2025 8-K Terminated a material agreement; Shareholder vote results; Regulation FD disclosure Oct 20, 2025 8-K Entered a material agreement Oct 17, 2025 8-K Entered a material agreement; Modified rights of security holders; Amended charter or bylaws Aug 26, 2025 10-Q Quarter ended 2025-06-30 Aug 14, 2025 8-K Results of operations (earnings release) Aug 14, 2025 8-K Entered a material agreement; Unregistered sale of equity Jul 2, 2025 8-K Entered a material agreement; Regulation FD disclosure May 22, 2025 10-Q Quarter ended 2025-03-31 May 15, 2025 8-K Results of operations (earnings release) May 15, 2025 8-K Entered a material agreement May 8, 2025 8-K Entered a material agreement Apr 14, 2025 8-K Entered a material agreement Apr 3, 2025 10-K/A Fiscal year ended 2024-12-31 Mar 28, 2025 8-K Entered a material agreement Mar 26, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 24, 2025 10-K Fiscal year ended 2024-12-31 Mar 24, 2025 8-K Delisting notice or listing-rule failure Jan 10, 2025 8-K Other events Dec 23, 2024 8-K Entered a material agreement Nov 25, 2024 10-Q Quarter ended 2024-09-30 Nov 14, 2024 8-K Results of operations (earnings release) Nov 14, 2024 8-K Entered a material agreement Nov 6, 2024 8-K Entered a material agreement; Terminated a material agreement; Triggering event accelerating an obligation Oct 31, 2024 8-K Entered a material agreement; Unregistered sale of equity Oct 28, 2024 8-K Entered a material agreement; Triggering event accelerating an obligation; Unregistered sale of equity Oct 3, 2024 8-K Entered a material agreement; Unregistered sale of equity Sep 25, 2024 8-K Entered a material agreement Sep 6, 2024